NEWBRY — Newbury Pharmaceuticals AB Income Statement
0.000.00%
Last trade - 00:00- SEK62.40m
- SEK50.73m
- SEK36.83m
- 35
- 37
- 17
- 16
Annual income statement for Newbury Pharmaceuticals AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 2.83 | 5.52 | 10.3 | 36.8 |
| Cost of Revenue | ||||
| Gross Profit | -2.35 | -6.16 | -6.9 | -2.94 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 8.45 | 20.2 | 29.9 | 50.9 |
| Operating Profit | -5.62 | -14.7 | -19.6 | -14.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -5.56 | -14.7 | -19.4 | -15.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -5.56 | -14.7 | -19.4 | -15.4 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -5.56 | -14.7 | -19.4 | -15.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -5.56 | -14.7 | -19.4 | -15.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.253 | -0.751 | -0.995 | -0.635 |